Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Researchglp-1sglt-2chronic kidney diseasediabetes

GLP-1 Drugs and SGLT-2 Inhibitors Linked to Slower Kidney Decline

Reported analysis associates both drug classes with reduced loss of kidney function, adding to evidence beyond glycemic and weight effects.

PR
By Priya Raman · Science Reporter
Sep 17 00:07 ETSource: News-Medical

The wire

  1. 01Research reported by News-Medical links GLP-1 receptor agonists and SGLT-2 inhibitors to slower kidney function decline.
  2. 02Renal protection would broaden the clinical rationale for both classes in diabetes and chronic kidney disease.
  3. 03Study design, population size and effect magnitude were not specified in the excerpt.

From the source

GLP-1 drugs and SGLT-2 inhibitors linked to slower kidney decline

Read at news.google.com